In Q4 2023, Deerfield Management held 155 positions worth $4.3B. They initiated 110 new positions and exited 34. Their largest holding was NUVL ($1.5B). Portfolio value grew +32.1% versus the prior quarter.
Frequently asked questions
What stocks did Deerfield Management own in Q4 2023?
Deerfield Management held 155 biotech stocks in their 13F portfolio in Q4 2023. Their top positions include NUVL, GKOS, VTRS, NTRA, CPRX. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Deerfield Management's portfolio worth in Q4 2023?
Deerfield Management's tracked biotech portfolio was worth $4.3B across 155 positions, with total assets under management of approximately $16B. Portfolio values are based on 13F filings with the SEC.
What did Deerfield Management buy in Q4 2023?
Deerfield Management initiated 110 new positions in Q4 2023, including OSCR, EMBC, GLPGF, PHVS, NKTX and 105 more. They also increased 19 existing positions.
What did Deerfield Management sell in Q4 2023?
Deerfield Management fully exited 34 positions in Q4 2023, including PCRX, PACB, MIRM, KRYS, IOVA and 29 more. They also trimmed 6 existing positions.
Is Deerfield Management a biotech fund?
Multi-strategy healthcare fund with one of the longest track records in the space. Deerfield invests across public equity, private equity, structured credit, and royalties in healthcare. Known for creative financing structures and deep industry relationships across pharma and biotech.
Want AI analysis, insider signals, and catalyst overlays for Deerfield Management?
View latest Deerfield Management portfolio →